SRC Signaling Pathway Insulinsensitivit
T higModel Power ON Estimation Insulinsensitivit, T high blood pressure, or lipids. Compares exenatide insulin, exenatide was compared with insulin analogue biphasic insulin aspart 70/30 and insulin glargine. The results of these studies show that exenatide was at least not inferior to insulin in reducing HbA1c, and can provide better embroidered with the postprandial glucose and reduced K Bodyweight. The dosage of insulin in these studies were not optimal. In the study comparing exenatide BIASP to 30, the average t Possible total dose 24.4 units per day, which saw a 1.0% reduction in HbA1c. A dose of 78.5 units per day has been entered in the INITIATE study what Born a reduction of 2.8% in HbA1c used.
In the study comparing insulin glargine, exenatide was the daily dose of 25 U / d, compared with 47 U / d in the treatment TARGET trial. We do not know how to compare exenatide Bendamustine optimized properly with insulin, because insulin has a capacitance Hypoglycemic t, which is limited only by the potential for hypoglycaemia Chemistry is. Exenatide: impact on safety and adverse events associated with exenatide h most common dose-ngig nausea, vomiting and diarrhea k can severity and abundance of H l to reduce through prolonged treatment. Nausea in studies with a duration of 16 to 30 weeks at 51% of the patients have been reported exenatide SU, 45% of patients Exenatide MET, 5% of patients, which again Exenatide u SU MET and 40% of those who oivent TZDs exenatide again.
In the analysis of two years together, the incidence of nausea, 39% w During the week 0 10 with the intention of the f Rderf Hige Bev Treat POPULATION, and 8% per week 100 104 among the 283 patients in the intent to treat the Bev POPULATION finished with 2 years of treatment. There were significantly h Higher values of nausea, vomiting and diarrhea in studies comparing insulin glargine, exenatide. These side effects have been associated with increased FITTINGS rate of removal in the exenatide group compared to insulin glargine and 9% in the exenatide TZD study together. Dizziness was reported in 15% and 16% in patients receiving exenatide or exenatide SU MET, compared to 7% and 8% of patients who again U SU or MET alone. Exenatide is obtained with a FITTINGS risk of hypoglycaemia Mie are assigned, when used in combination with SU, but not to this level.
Treated in tests AMIGO, mild hypoglycaemia Mie in 3% of patients with SU, were that. In 36% of subjects SU Exenatide, 5.3% of subjects and 27.8% of exenatide MET MET SU volunteers exenatide Mild to moderate hypoglycaemia Mie went up to 12% of the respondents second Verl EXTENSIONS with 4 F Lle of severe hypoglycaemia Was mie in patients observed SU. There were no F Lle of severe hypoglycaemia Was mie w During the Verl Observed EXTENSIONS study MET. With a low incidence of hypoglycaemia Premiums occurred when exenatide was added to TZD therapy, and in the experiment with insulin glargine compared. The collected data show that 38% of patients without Antique Bodies as low significantly adverse clinical consequences. H Here titer antique Bodies were in 6% of patients within 30 weeks after the clinical trials of exenatide added MET or SU and in 9% of patients again U exenatide observed in combination with TZDs. Average MET about the H Half of patients with h Herem titer Antique Body in the SU-tests, and one gr Erer proportion of the study TZD experienc .